en
svPress releases
Regulatory press release 2021-04-20
Notice of annual general meeting of Xspray Pharma AB (publ)
Regulatory press release 2021-04-08
Xspray Pharma announces the results of two bioequivalence studies with adjusted tablet formulation of HyNap-Dasa (ANDA)
Regulatory press release 2021-03-19
Xspray Pharma publishes its annual report for 2020
Regulatory press release 2021-02-25
Xspray Pharma publishes Interim report Q4, January – December 2020
Regulatory press release 2021-02-17
Nomination Committee proposes Anders Ekblom as new Chairman of the Board in Xspray Pharma
Regulatory press release 2021-01-29
Number of shares and votes in Xspray Pharma
Regulatory press release 2021-01-26
Warrant holders exercise all warrants within the framework of the incentive program
Regulatory press release 2021-01-22
Xspray Pharmas study with modified formulation of HyNap-Dasa has now started
Regulatory press release 2021-01-14
Xspray Pharma announces results from additional bioequivalence study and provides update regarding upcoming regulatory applications for ANDA and 505(b)(2)
Regulatory press release 2020-12-29
Xspray Pharma’s HyNap-Nilo receives FDA Orphan Drug Designation for the treatment of Chronic Myeloid Leukemia
Subscribe
IR contact
Christina Malmberg Hägerstrand, SVP Communications & IR